P584 Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry
ECCO'20 Vienna
2020
P586 Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
ECCO'20 Vienna
2020
P587 Adalimumab in pediatric Crohn’s disease: A long-term multi-centre real-world experience
ECCO'20 Vienna
2020
P588 vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
ECCO'20 Vienna
2020
P589 Longer-term outcomes in patients with Crohn’s disease who are primary non-responders to anti-TNF in a single UK centre
ECCO'20 Vienna
2020
P590 Outcomes of patients treated with sequential anti-TNF therapy in a tertiary referral centre
ECCO'20 Vienna
2020
P591 Therapeutic management in inflammatory bowel disease: Differences in two IBD inception cohorts: 1991–93 and 2010–11 enrolled in the north-west of Spain
ECCO'20 Vienna
2020
P592 Frequency and causes of prolongation of the induction course of tofacitinib in patients with ulcerative colitis in conditions of real clinical practice
ECCO'20 Vienna
2020
P593 Predictors of steroid-resistance in severe colitis of inflammatory bowel disease
ECCO'20 Vienna
2020
P594 Increased levels of stress, anxiety and depression among patients with CD and UC
ECCO'20 Vienna
2020
P595 Feasibility and performance of a fully automated endoscopic disease severity grading tool for ulcerative colitis using unaltered multisite videos
ECCO'20 Vienna
2020
P596 Risk of colorectal cancer and other malignancies in association with the use of thiopurines, tumour necrosis factor antagonists or mesalazine
ECCO'20 Vienna
2020
P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis
ECCO'20 Vienna
2020